Clinical Trial Update: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trials update reports a Phase 1/2 study evaluating EP0062 as both a monotherapy and in combination therapy for advanced or metastatic AR+/HER-2-/E…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• EP0062

Snippet

Sponsor: Ellipses Pharma | Conditions: Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING